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Background. The Constant Load Treadmill Test (CLTT) is currently the primary method used to measure walking impair-
ment in patients with peripheral vascular disease. The aim of this study was to compare the CLTT and PADHOC device as
assessments of walking impairment.
Methods. 55 patients with intermittent claudication underwent a CLTT and a Double Physiological Walking Test
(DPWT) using the PADHOC device. Health-related quality of life was measured using the Short Form 36 and the
Claudication Scale.
Results. The initial claudication and maximum walking distance from the first part of the DPWT showed the best corre-
lation with domains of pain and physical function.
Conclusions. The DPWT is more representative of the functional incapacity experienced by patients with intermittent
claudication. We believe that the PADHOC is a suitable alternative to the CLTT in the assessment of this patient group.
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Intermittent claudication is the most common present-
ing symptom of patients with peripheral arterial dis-
ease. The measurement of walking distances is an
integral part of the initial assessment of the claudi-
cant. The estimation of walking distance is inaccu-
rate.1 The Constant Load Treadmill Test (CLTT) is
felt to be the ‘‘gold standard’’ laboratory determinant
of walking distances in claudicants, but it is asso-
ciated with a number of shortcomings.2 A high pro-
portion of claudicants are unable to undertake or
complete a CLTT, usually due to concomitant comor-
bidity.3e4 Differing treadmill protocols have limited
the potential of comparison between studies and the
use of the treadmill itself is limited to predominately
a laboratory-based setting.5e7 The PADHOC (Periph-
eral Arterial Disease Holter Control Device) device
and the associated Double Physiological Walking
Test (DPWT) is a novel way of determining a claudi-
cants walking distance.3,8 The aim of this study was
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measure of functional incapacity in claudicants, when
compared to a CLTT.
Patients and Methods
Ethical committee approval was given for this study
and informed consent obtained from each patient en-
rolled. Fifty-five patients with intermittent claudica-
tion were recruited into this prospective study over
a year-long period. All the patients recruited to this
study had been invited to take part in a prospective
study being undertaken by the department determin-
ing the effect of different treatment modalities in inter-
mittent claudication. Inclusion criteria were the ability
to undergo both a CLTT and the DPWT using the
PADHOC device. Patients with severe exercise limit-
ing disease were excluded (i.e. severe ischaemic heart
disease, chronic obstructive pulmonary disease and
osteoarthritis). Patients with critical ischaemia and tis-
sue loss, as defined by the Transatlantic Inter-Society
Consensus (TASC) document, were also excluded
from the study.9 Each patient underwent both
a CLTT and the DPWT. Both tests were performed
on the same day with a one-hour rest period betweenerved.
652 P. A. Coughlin et al.them. The CLTT consisted of a treadmill test at a speed
of 2.5 km/h at an incline of 10  for a maximum of
5 min. Pre and post-exercise ankle brachial pressure
indices (ABPI’s) were determined, as were the initial
claudication distance (ICDt) and the maximum walk-
ing distance (MWDt). Disease severity was thus deter-
mined using SVS/ISCVS criteria.10
The PADHOC device
This device consists of a main unit worn by the
patient, on a belt, which contains a removable com-
puter card that records the data (Fig. 1). It is con-
nected to two ultrasound sensors (a transmitter
sensor and a receiver sensor), each fixed over the pa-
tient’s medial malleoli by ankle straps, and to a con-
trol module held in the patient’s hand. The test is
performed indoors on level ground. As the patient
commences walking, they press the green button.
At the onset of claudication pain, the patient presses
the yellow button and the red button is then pressed
when the patient can walk no further. The patient
then rests, standing for one minute, and the test is
Fig. 1. The main unit worn by the patient.Eur J Vasc Endovasc Surg Vol 32, December 2006then repeated. For each test ICD, MWD and speed
are calculated and the whole test is known as the
Double Physiological Walking Test (DPWT). The belt
pack receives and processes the signal and displays
the results on a LED screen. The device has a number
of advantages.
Principle of the PADHOC device
The measurement principle of the PADHOC device is
based upon ultrasound telemetry. Walking distance is
calculated by the continuous measurement of the
distance between the patients medial malleoli. The
transmitting sensor sends an ultrasound signal to
the receiver sensor 64 times a second. The main unit
measures the time taken for the signal to travel from
one sensor to the other. The distance between the
medial malleoli is calculated by multiplying this time
by the sound propagation speed. All measurements
of this distance are plotted as a sinusoidal curve. Each
oscillation on the curve corresponds to one step. Maxi-
mum variations correspond to the moment when both
feet touch the ground. Therefore, each maximum vari-
ation represents the actual walking distance travelled
during one step. The sum of all the maximum intermal-
leolar distances is used to calculate the walking
distance. This allows the parameters ICD, MWD and
walking speed to be measured for both parts of the
DPWT.
Principle of the double physiological walking tests
with the PADHOC system
During the walking test, the pain that causes the pa-
tient to stop is thought to occur at the same time as
the decrease in ankle pressure (Fig. 2).8 The speed at
which the ankle pressure recovers to its initial pre-
exercise value varies according to the functional state
of the collateral circulation. After the patient has res-
ted, standing, for one minute the pain subsides but the
ankle pressure may still remain at a lower value
than that prior to the initial walking period. It would
seem reasonable that the longer time it takes for
the ankle pressure to recover to its original value, the
shorter a second walking test carried out under the
same conditions will be. Using this principle, disease
severity can be measured by determining distance
ratios for both ICD and MWD between the first and
second walking tests (ICD2/ICD1 and MWD2/MWD1
respectively), with lower values representing more
severe disease.
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Each patient also completed the generic Short Form 36
(SF 36) QoL instrument. This was undertaken on the
same day as the two walking assessments. The SF 36
is a well-validated generic QoL tool. It was developed
from a previous questionnaire e the Medical Out-
comes Study General Health Survey Instrument e
with the aim of providing a short yet comprehensive
and psychometrically sound instrument.11 It contains
36 questions covering eight health domains. Ques-
tions for each domain are coded, summed and trans-
formed on a scale of 0 (worst possible health) to 100
(best possible health). The SF 36 has been validated
in population studies.12,13 Furthermore, it has been
suggested that the SF 36 is the most appropriate
generic QoL tool to be used in patients with lower
limb ischaemia.14 The health domains for physical
function and pain (Physical Function (PF), Role Phys-
ical (RP) and Bodily Pain (BP)) were used to reflect the
patients functional incapacity.
The Claudication Scale (CLAU-S)
The CLAU-S is a disease-specific instrument, which
has been developed in Germany.15 It consists of 47
items covering the 5 health dimensions of Daily
Living, Pain, Social Life, Disease-Specific Anxiety
and Mood. For all domains, the score is calculated
as the mean of the completed items of each domain
and the results transformed so that for all domains
0 represents the worse and 100 the best possible QoL.
The health domains of both questionnaires can be
conveniently grouped into physical function, bodily
pain, social function and psychological function. The
Fig. 2. Representation of the principle behind the Double
Physiological Walking Test.health domains for physical function and pain from
the two QoL tools have been used as markers of func-
tional incapacity in this study.
Statistical Analysis
All values are expressed as median (interquartile
range) except where specified. Spearman rank correla-
tion coefficient (rs) was used to determine correlation
between walking distances and QoL scores. Signifi-
cance was determined as a p value < 0.050. Statistical
analysis was performed using Analyse-it software
(Leeds, U.K.)
Results
Demographics
Of the 55 patients recruited, 30 were men and the
overall median age was 69 years (range 48e85 years).
Seven patients had mild claudication, 29 moderate
claudication and 19 severe claudication as determined
by SVS/ISCVS criteria.9 Median pre exercise ABPI
was 0.73 (0.58e0.82) and median post exercise
ABPI was 0.53 (0.36e0.71). Of the 55 patients, 7
were diabetic, 32 had a positive smoking history, 23
were known to be hypertensive and 28 known to be
hypercholesterolaemic.
Walking parameters for the CLTT and the DPWT
All patients were able to complete the CLTT and the
DPWT. The median ICDt was 30.5 metres (21e50
metres) and the median MWDt was 60 metres
(40e101 metres). The median ICD1 and MWD1 were
113.5 metres (68.75e165.5 metres) and 234 metres
(154.5e475.5 metres) respectively. The median ICD2
and MWD2 were 33 metres (4e90 metres) and 127
metres (81e265 metres) respectively. The median
ICD ratio (ICD2/ICD1) from the DPWT was 0.35
(0.04e0.78) and the median MWD ratio (MWD2/
MWD1) from the DPWT was 0.57 (0.42e0.81).
Walking parameters and QoL domains (Table 1)
The ICDt had lower correlation coefficients for the do-
mains of pain and physical function compared to the
ICD1. The MWDt had lower correlation coefficients for
the domains of pain and physical function compared
to the MWD1 apart from the CLAU-S domain of Daily
Living. The ICD2 showed a weak correlation with
the health domains of Physical Function and RoleEur J Vasc Endovasc Surg Vol 32, December 2006
654 P. A. Coughlin et al.Table 1. Comparison between initial claudication distances (ICD) for the treadmill test and the first part of the DPWT with the QoL
health domains. Values are Spearman Rank Correlation Coefficient (rs)
QoL health domain ABPI
Pre
ABPI
Post
Treadmill
ICD
Treadmill
MWD
PADHOC
ICD1
PADHOC
MWD1
PADHOC
ICD2
PADHOC
MWD2
Physical
activity
CLAU-S Daily
Living
0.06 0.11 0.50* 0.53* 0.58* 0.46* 0.18 0.32y
SF-36 Physical
Function
0.18 0.02 0.60* 0.66* 0.63* 0.68* 0.31y 0.63*
SF-36 Role Physical 0.12 0.04 0.32y 0.35y 0.49* 0.63* 0.26y 0.43*
Pain CLAU-S Pain 0.23 0.08 0.33y 0.30y 0.39* 0.32y 0.34* 0.31y
SF-36 Bodily Pain 0.06 0.02 0.39* 0.39* 0.46* 0.51* 0.04 0.32y
* p< 0.01.
y p< 0.05.Physical (SF 36) and the domain of Pain (CLAU-S).
There was no significant correlation between the do-
mains of Daily Living (CLAU-S) and Bodily Pain (SF
36) and the ICD2. The MWD2 has a significant correla-
tion with all of the health domains analysed. All walk-
ing distances obtained from both the CLTT and the
DPWT excluding the ICD2 significantly correlated
with all QoL domains for Pain and Physical function.
The ICD2 failed to correlate significantly with either
the CLAU-S Daily Living or the SF-36 Bodily Pain
domains. Disease severity as measured from both
the DPWT (ICD2/ICD1.and MWD2/MWD1) or the
CLTT (ISCVS/SVS criteria) did not correlate with
any of the markers of functional incapacity (data not
shown).
Discussion
The assessment of intermittent claudication is multi-
faceted. Assessment of the patient’s co-morbidity
will determine the relative fitness for any form of
intervention with parallel risk factor profiling and
subsequent modification being obligatory. The assess-
ment of a patients walking distance plays a role in de-
termining disease severity as well as facilitating the
assessment of the overall incapacity experienced by
the claudicant. Given that claudication distances are
poorly estimated, an accurate assessment of walking
status is needed for studies.1 The overall assessment
of the claudicant has recently been supplemented by
the introduction of quality of life analysis. Health, as
defined by the World Health Organisation, is not
only ‘‘the absence of infirmity but also a state of phys-
ical, social and mental well being’’.16 The design of the
majority of QoL tools is largely based upon this defi-
nition. The SF 36 is a well-validated generic QoL ques-
tionnaire that has been routinely used in a number of
claudication studies.7,14,17,18 It is simple and easy to
understand and is relatively quick to complete.Eur J Vasc Endovasc Surg Vol 32, December 2006Indeed it has been suggested that the SF 36 should
be looked upon as the ‘‘gold standard’’ generic QoL
tool for the patients with peripheral arterial disease.14
Functional incapacity itself is a difficult concept to ac-
curately measure. The Walking Impairment Question-
naire (WIQ) has been used in claudicant groups to
measure walking ability.19 The questionnaire ad-
dresses the issues of walking distance, walking speed
and stair-climbing capacity. It correlates well with ob-
jective walking ability in patients with and without
peripheral arterial disease.19 However, overall physi-
cal function is not limited solely to walking ability
and indeed in the claudicant population it is likely
that perceived pain will also affect physical function.
Some studies have used more specific markers of
physical function, such as the Leisure Time Physical
Activity Questionnaire (LTPAQ) and the Stanford 7-
day Physical Activity Recall Questionnaire (PARQ)
but, their limited use restricts the opportunity for
comparison between studies.20,21 The SF 36 addresses
a wide variety of issues with regard to physical func-
tion. The SF 36 not only determines the effect of dis-
ease on walking but also addresses other activities
including shopping, bathing and dressing. It also asks
the patient to determine the effect of their physical
health on their work and daily activities.
For many years, the CLTT has been the gold
standard method of determining walking distances in
patients with intermittent claudication. Despite this
widespread use, there are a number of associated defi-
ciencies with the CLTT. The rigidity of the test parame-
ters with regard to speed and incline, has not only
limited the number of claudicants able to undertake
a CLTT but results in an artificial setting with regard
to the intensity of the work undertaken by the claudi-
cant. Due to this, it has been suggested that the test
does not reflect the actual functional incapacity experi-
enced by the claudicant on a day-to-day basis. The
graded treadmill test has similar associated problems
again due to the artificial test environment. Comparison
655The PADHOC Devicebetween studies is limited due to the use of variable
study protocols.5e7 A number of other methods have
been developed to try to improve upon the assessment
of walking ability.2,22 The 6 min walking test, although,
probably more representative of daily walking ability is
limited by the rigid test criteria that need to be met for
the results to be reliable with the subsequent chance of
inter-observer variability.
The PADHOC was designed to overcome all these
problems. It is safe and simple to use and the results
obtained are not affected by observer variation. It al-
lows the claudicant to walk at their normal pace there-
fore mimicking the conditions they experience on
a daily basis. Claudicants who are unable to undergo
a CLTT are therefore able to have an assessment of
their walking ability.4 The DPWT using the PADHOC
has been shown to correlate well with a CLTT.4 It had
been shown to accurately reflect improvements fol-
lowing therapeutic interventions although as yet its
ability to discriminate between arterial claudication
and other causes of leg pain has not been deter-
mined.23 The DPWT allows the measurement of ankle
pressures prior to and after exercise if so required. A
recent study of eighty patients had shown that in
older patients with intermittent claudication, objective
measures which include the ankle-brachial index,
time to maximum claudication pain on a graded exer-
cise test, and a 6-minute floor-walking distance corre-
lated with a self-reported, disease-specific and generic
quality of life.24
This study further supports the use of the PAD-
HOC as an alternative measure of walking ability.
The PADHOC shows superior correlation with
markers of physical function and pain for both the
ICD1 and MWD1 when compared to the treadmill
walking distances. The only exception to this is the
health domain of Daily Living (CLAU-S), which
shows superior correlation with the MWDt than
MWD1. The MWD2 of the DPWT also shows strong
correlation with the markers of physical function
and pain although the correlation coefficients are all
lower than those obtained for the MWD1.
The lack of correlation with the ICD2 is in keeping
with other studies of the PADHOC suggesting that its
only role in the assessment of the claudicant is in the
determination of disease severity using the ratio of
ICD2 to ICD1. Although the walking distance ratios
fail to correlate with functional impairment as deter-
mined by QoL analysis, previous work has shown
that diseases severity as determined by the DPWT cor-
relates with SVS/ISCVS criteria.4 This would suggest
that it is not solely the walking distances in a clau-
dicant population that affects their daily functional
incapacity. Correlation measures the strength ofa relation between two variables and not the agree-
ment between them. However, although both tests
are measuring walking distances, the tests differ in
the degree of stress placed upon the patients. One
would expect different walking distances for each
test in the same patients. The use of correlation is
therefore used to determine which walking test
more closely reflects a marker of functional incapacity
(QoL tools). The difference in correlation coefficients
with regard to ICD are small and therefore it may
well be that there is really no clinical difference in
functional incapacity if one was to consider solely
the ICD. However, the differences in correlation coef-
ficients when considering the MWD of the two walk-
ing tests and the QOL scores are larger with regard to
Role Physical domain and to a lesser extent the Bodily
Pain domain (MWD1 only) and therefore could be
considered to more likely reflect a clinical difference.
Overall, the results would suggest that the PADHOC
device and the subsequent DPWT is more representa-
tive of the functional incapacity experienced by the
claudicant. We suggest that the PADHOC is a worth-
while alternative to the CLTT for the assessment of
the walking ability of all claudicants in clinical trials
used in combination with a QoL tool.
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